Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 4
2020 4
2021 5
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer.
Moyer CL, Ivanovich J, Gillespie JL, Doberstein R, Radke MR, Richardson ME, Kaufmann SH, Swisher EM, Goodfellow PJ. Moyer CL, et al. Among authors: radke mr. Cancer Res. 2020 Feb 15;80(4):857-867. doi: 10.1158/0008-5472.CAN-19-1991. Epub 2019 Dec 10. Cancer Res. 2020. PMID: 31822495 Free PMC article.
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCA-mutant ovarian cancer.
Gupta N, Huang TT, Nair JR, An D, Zurcher G, Lampert EJ, McCoy A, Cimino-Mathews A, Swisher EM, Radke MR, Lockwood CM, Reichel JB, Chiang CY, Wilson KM, Cheng KC, Nousome D, Lee JM. Gupta N, et al. Among authors: radke mr. Sci Transl Med. 2023 Jun 21;15(701):eadd7872. doi: 10.1126/scitranslmed.add7872. Epub 2023 Jun 21. Sci Transl Med. 2023. PMID: 37343085 Free PMC article. Clinical Trial.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. Lin KK, et al. Among authors: radke mr. Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13. Cancer Discov. 2019. PMID: 30425037 Free article. Clinical Trial.
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. Rodler E, et al. Among authors: radke mr. Lancet Oncol. 2023 Feb;24(2):162-174. doi: 10.1016/S1470-2045(22)00739-2. Epub 2023 Jan 6. Lancet Oncol. 2023. PMID: 36623515 Free PMC article. Clinical Trial.
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Kim JW, et al. Among authors: radke mr. J Clin Oncol. 2023 Feb 1;41(4):871-880. doi: 10.1200/JCO.21.02947. Epub 2022 Oct 18. J Clin Oncol. 2023. PMID: 36256912 Free PMC article. Clinical Trial.
Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.
Prakash R, Rawal Y, Sullivan MR, Grundy MK, Bret H, Mihalevic MJ, Rein HL, Baird JM, Darrah K, Zhang F, Wang R, Traina TA, Radke MR, Kaufmann SH, Swisher EM, Guérois R, Modesti M, Sung P, Jasin M, Bernstein KA. Prakash R, et al. Among authors: radke mr. Proc Natl Acad Sci U S A. 2022 Sep 20;119(38):e2202727119. doi: 10.1073/pnas.2202727119. Epub 2022 Sep 13. Proc Natl Acad Sci U S A. 2022. PMID: 36099300 Free PMC article.
Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, Swisher EM, Liu ET. Menghi F, et al. Among authors: radke mr. Sci Transl Med. 2022 Jul 6;14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926. Epub 2022 Jul 6. Sci Transl Med. 2022. PMID: 35857626 Free PMC article.
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E, Huang TT, Nair JR, Zurcher G, McCoy A, Nousome D, Radke MR, Swisher EM, Lipkowitz S, Ibanez K, Donohue D, Malys T, Lee MJ, Redd B, Levy E, Rastogi S, Sato N, Trepel JB, Lee JM. Giudice E, et al. Among authors: radke mr. Nat Commun. 2024 Mar 30;15(1):2805. doi: 10.1038/s41467-024-47215-6. Nat Commun. 2024. PMID: 38555285 Free PMC article. Clinical Trial.
Molecular phylogenetics and species-level systematics of Baylisascaris.
Camp LE, Radke MR, Shihabi DM, Pagan C, Yang G, Nadler SA. Camp LE, et al. Among authors: radke mr. Int J Parasitol Parasites Wildl. 2018 Oct 22;7(3):450-462. doi: 10.1016/j.ijppaw.2018.09.010. eCollection 2018 Dec. Int J Parasitol Parasites Wildl. 2018. PMID: 30568876 Free PMC article.
Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
Sullivan MR, Prakash R, Rawal Y, Wang W, Sung P, Radke MR, Kaufmann SH, Swisher EM, Bernstein KA, Jasin M. Sullivan MR, et al. Among authors: radke mr. Cold Spring Harb Mol Case Stud. 2021 Apr 8;7(2):a006083. doi: 10.1101/mcs.a006083. Print 2021 Apr. Cold Spring Harb Mol Case Stud. 2021. PMID: 33832919 Free PMC article.
18 results